Annovis Bio Files Patent for New Composition of Matter for Buntanetap
Annovis Bio announced filing a new composition of matter patent with the U.S. Patent and Trademark Office for novel crystalline forms of buntanetap, enhancing its solubility and stability for treating neurodegenerative disorders like Alzheimer’s and Parkinson’s. This builds upon a provisional patent from June 2023. The most stable crystal form has been selected for animal bridge studies and manufacturing process development. These studies were submitted to the FDA and will be discussed in July. This patent provides 20-year protection, aiding the company's drug development and market introduction plans.
- Filing of a new composition of matter patent for buntanetap.
- Enhanced solubility and stability of the new crystalline forms of buntanetap.
- 20-year term protection for the new crystalline forms and their uses.
- Selection of the most stable crystal form for further development and FDA discussions.
- negative
- None.
The new composition of matter patent for the crystalline form of buntanetap holds significant value in the medical research landscape, particularly for neurodegenerative conditions like Alzheimer's and Parkinson's diseases. The enhanced solubility and stability of crystalline forms are noteworthy as they can lead to better drug efficacy by allowing for more consistent and predictable delivery. This patent effectively extends the exclusivity period for Annovis Bio, offering a 20-year protection that will enable the company to recoup research and development costs and invest further in innovation. This is a critical step towards obtaining FDA approval and ultimately commercializing the drug, which can be a game-changer for patients suffering from these debilitating conditions.
From a financial perspective, the patent filing for a new solid form of buntanetap is a strategically important development for Annovis Bio. The enhanced stability and solubility of the drug should lower production costs and improve manufacturing efficiency, potentially leading to better profit margins. Moreover, securing a composition of matter patent provides a significant competitive advantage by protecting the drug from generic competition for 20 years. This stability can attract more investors and increase shareholder confidence. There’s also a potential for a boost in stock prices as the market often responds positively to news of patent filings, especially when it pertains to advancements in late-stage clinical drug developments.
Analyzing the market impact, the patent on the new crystalline form of buntanetap could position Annovis Bio as a stronger player in the neurodegenerative drug market. Patents provide a legal monopoly which is important in the pharmaceutical industry. This move will likely bolster their competitive edge, making it challenging for other companies to develop similar treatments. The market for Alzheimer's and Parkinson's treatments is substantial and growing and securing this patent could increase the company's market share. Investors should note that while patent filings signal potential, they also come with risks related to the drug's final efficacy and approval processes.
MALVERN, Pa., June 26, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), announces the filing of the new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023.
This patent covers novel crystalline forms of buntanetap and their use for treating and/or preventing various neurodegenerative conditions. Crystalline forms offer significant advantages over less structured forms, including better solubility and stability. The most stable crystal form of buntanetap (CAS# 3032752-92-1) has been selected as the new lead compound for animal bridge studies and for developing a manufacturing process. The bridge studies were submitted to the FDA and will be discussed in July. The goal is to continue development of our drug and file the NDA with the new crystal form.
“The invention of a new solid form of our drug, buntanetap, and the subsequent patent filing represent groundbreaking milestones for our company. This achievement will allow us not only to continue advancing our pipeline, but also to enhance the drug's properties, ultimately providing greater benefits to our patients,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis.
A composition of matter patent comes with protection for the new buntanetap crystalline form and all its uses for a 20-year term. The composition of matter patent is the single most important patent for any pharmaceutical company developing a new drug because it provides adequate runway to develop a drug and bring it to market.
About Buntanetap
Buntanetap (formerly known as Posiphen or ANVS401) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This action improves synaptic transmission, axonal transport, and reduces neuroinflammation. Dysregulation of these pathways has been shown to cause nerve cell degeneration and ultimately nerve cell death. By targeting these pathways, buntanetap has the potential to reverse neurodegeneration in Alzheimer’s, Parkinson’s, and other neurodegenerative diseases, thereby aiming to restore brain function and improve the quality of life for patients.
About Annovis Bio, Inc.
Headquartered in Malvern, Pennsylvania, Annovis Bio Inc. is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at https://www.Annovisbio.com/email-alerts
Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, the Company's plans related to clinical trials. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include, but are not limited to, those related to patient enrollment, the effectiveness of buntanetap, and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety, and tolerability of buntanetap. Additional risk factors are detailed in the Company's periodic filings with the SEC, including those listed in the "Risk Factors" section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements in this press release are based on information available to the Company as of the date of this release. The Company expressly disclaims any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contacts
Annovis Bio, Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact
Scott McGowan
InvestorBrandNetwork (IBN)
Phone: 310.299.1717
IR@annovisbio.com
Investor Website
FAQ
What recent patent did Annovis Bio file for buntanetap?
What are the benefits of the new crystalline forms of buntanetap?
What is the duration of the patent protection for the new crystalline forms of buntanetap?
When was the provisional patent for buntanetap filed?
What is the next step for the development of the new crystalline forms of buntanetap?
What is the most stable crystal form of buntanetap selected for development?
